Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Role of TREM-1 as a Novel Biomarker in HER-2 Negative Breast Cancer: a Molecular and Clinical Study

NCT06950671 is registered in ClinicalTrials.gov with Rahma Esam Salama Esawi as lead sponsor.

NCT NCT06950671
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06950671 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Role of TREM-1 as a Novel Biomarker in HER-2 Negative Breast Cancer: a Molecular and Clinical Study
Lead sponsor
Rahma Esam Salama Esawi
Phase
Observational
Overall status
Not yet recruiting
Start date
September 15, 2025
Completion date
September 30, 2029
Enrollment
1 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer invasive, breast cancer stage i, breast cancer stage ii, breast cancer stage iii